Start | Browse by Day | Author Index

Scientific Poster Presentations, II

Tuesday, October 23, 2012: 8:00 AM-10:00 AM
Westin Diplomat Resort
1
Observed incidence of linezolid-associated serotonin syndrome during concomitant serotonergic therapy
Melanie R. Woytowish, Pharm.D.1 and Lena Maynor, Pharm.D.2
1West Virginia University Healthcare, Morgantown, WV
2West Virginia University School of Pharmacy, Morgantown, WV
2E
A comparative study of patients with acute promyelocytic leukemia receiving all-trans retinoic acid with and without voriconazole: effect on differentiation syndrome
Jason N. Barreto, PharmD, BCPS, John C. Kuth, PharmD, BCOP, Candy S. Peskey, PharmD, BCPS and Mrinal M. Patnaik, MBBS
Mayo Clinic, Rochester, MN
3
Converting Between Glycine-Stabilized Intravenous Immune Globulin Products: Incidence of Adverse Events
Ginger Morris, Pharm.D. and Eric M. Tichy, Pharm.D., BCPS
Yale-New Haven Hospital, New Haven, CT
4
Characterization of Dabigatran discontinuation in the community setting
Amanda Kerr, Pharm.D., Tina G. Hipp, Pharm.D. and Becky J. Szymanski, PharmD.
Carolinas Medical Center - NorthEast, Concord, NC
5
Evaluation of anticoagulation overlap therapy for the treatment of venous thromboembolism at an academic medical center
Melissa M. Chesson, Pharm.D., BCPS1, Carissa J. Fischer, Pharm.D.1 and Candace Stearns, Pharm.D., BCPS2
1Mercer University College of Pharmacy and Health Sciences, Atlanta, GA
2Emory Healthcare, Atlanta, GA
6E
Dabigatran and warfarin: comparative analysis of safety and cost
Niyati H. Vakil, PharmD, Molly Leber, PharmD, BCPS, Gina Bliss, PharmD and Marina Yazdi, PharmD, BCPS
Yale-New Haven Hospital, New Haven, CT
8
Evaluation of a pharmacy-driven erythropoiesis-stimulating agent utilization program
Erin K. Hennessey, PharmD1, Andrew J. Crannage, PharmD, BCPS2, Joy R. Abu-Shanab, PharmD, BCPS3, Matthew J. Korobey, PharmD, BCPS3 and Julie A. Murphy, PharmD, BCPS, FASHP, FCCP1
1St. Louis College of Pharmacy / Mercy Hospital St. Louis, St. Louis, MO
2St. Louis College of Pharmacy, St. Louis, MO
3Mercy Hospital St. Louis, St. Louis, MO
9
Evaluation of missed opportunities for pharmacotherapy management of heart failure in primary care
Kristyn Mulqueen, Pharm.D., BCPS and Shawn Anderson, Pharm.D., BCACP
Department of Veterans Affairs, Gainesville, FL
10E
Effect of Intrathecal Bupivacaine Lidocaine combination on Motor Block and Analgesia Period
Sara El-Adawy, master, &, board, of, pharmacotherapy
Ain-shams university,faculty of pharmacy, Cairo, Egypt
11
Implications on Vaccine Compliance Rates in an Internal Medicine Outpatient Clinic with the Implementation of a Pharmacist Driven Vaccination Assessment: Phase 2
Jamie M. Pitlick, PharmD, BCPS1, Abigail Yancey, Pharm.D.2 and Alicia B. Forinash, Pharm.D., BCPS, BCACP3
1St. Louis College of Pharmacy, St. Louis, MO
2St. Louis College of Pharmacy, St Louis, MO
3St. Louis College of Pharmacy, Saint Louis, MO
12
Association between venous thromboembolism and air pollution in an industrial North American city: implications for anticoagulation management
Holly H. Chiu, Pharm.D.1 and Peter Whittaker, PhD2
1Beaumont Hospital, Royal Oak, MI
2Wayne State University School of Medicine, Cardiovascular Research Institute and Dept of Emergency Medicine, Detroit, MI
13
Comparison of cefpodoxime versus cefuroxime axetil for acute sinusitis
Scot E. Walker, PharmD, MS, BCPS, BCACP
Facts & Comparisons, St. Louis, MO
14
Group Clinic Evaluation of Diabetes Related Measures of Control in Veterans with Poorly Controlled Type 2 Diabetes
Lauralee C. Gordon, PharmD1, Melaina K Perry, PharmD1, Rebecca J Cripps, PharmD, BCPS1, Regina F Cassidy, PharmD, BCPS, CDE1, Amy S Wilson, PharmD1 and M Shawn McFarland, PharmD, BCPS, BC-ADM2
1VA Tennessee Valley Healthcare System, Nashville, TN
2Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN
15
Decreasing Inappropriate Prescribing in Elderly Patients
Regina Ginzburg, Pharm.D. and Nicole Ng, Pharm.D.
St. John's University, Queens, NY
17
Upper extremity deep vein thrombosis: a retrospective cohort evaluation at a university teaching hospital antithrombosis clinic
Rebecca H. Stone, PharmD, Edith A. Nutescu, PharmD and Nancy L. Shapiro, Pharm.D.
University of Illinois at Chicago College of Pharmacy, Chicago, IL
18
Implications on Vaccine Compliance Rates with the Implementation of a Pharmacist Driven Vaccination Assessment: Phase 2
Abigail Yancey, Pharm.D., Jamie Pitlick, PharmD and Alicia Forinash, PharmD
St. Louis College of Pharmacy, St Louis, MO
19
Effect of pharmacy team interventions on monitoring rates for second-generation antipsychotics in a correctional setting
Philip J. Wenger, Pharm.D., BCPS and Kyle R. Mays, Pharm.D.
St. Louis College of Pharmacy, Saint Louis, MO
20
Pharmacist interventions and health care outcomes in a novel heart failure medication adherence clinic
Jennifer L. Johnson, PharmD1, Lynette R. Moser, PharmD2, Candice L. Garwood, PharmD3 and Melissa Lipari, PharmD4
1Detroit Medical Center - Harper University Hospital, Detroit, MI
2Wayne State University, Detroit, MI
3Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI
4Harper University Hospital, Detroit, MI
21E
Effects of a pharmacist-initiated outreach program on controller medication use and asthma control in non-adherent asthmatics
Kelly A. Gibas, PharmD, Amy M. Kramer, PharmD, Mary Ann Dzurec, PharmD and Paul R. Bandfield, PharmD
Kaiser Permenante, Parma, OH
43
Coaching to better medication adherence: The pharmacist as a health coach
CoraLynn B. Trewet, MS, PharmD1 and Jennifer R. Moulton, RPh2
1University of Iowa College of Pharmacy, Des Moines, IA
2Collaborative Education Institute, Des Moines, IA
44
Y-site physical compatibility of intensive care unit admixtures with cisatracurium
Jaime A. Foushee, Pharm.D., BCPS, Laura M. Fox, Ph.D., Lyndsay R. Gormley, Pharm.D. Candidate and Megan D. Sumner, Pharm.D. Candidate
Presbyterian College School of Pharmacy, Clinton, SC
45
Effect of sedation medication and daily awakening on delirium in the mechanically ventilated critically ill patient: a descriptive pilot study
Trevor L. Perry, PharmD, Julie Moon, PharmD, BCPS and Harminder Sikand, Pharm.D., FCSHP, FASHP
Scripps Mercy Hospital, San Diego, CA
46
Evaluation of procalcitonin (PCT) use for antibiotic discontinuation in medical intensive care patients at a community teaching hospital
Sara E. Jordan, PharmD, Lauren M Flannery, PharmD, Rodney K Kusumi, MD, Shiva D Rahmanian, MD, Kiran Devulapally, MD, Bradley R Harrold, MD, Phillip C Hawley, MD, Amy Creighton, MS, James J Jenkins II, PhD, Lauren A DiBenedetto, BS, Janelle Hartman, BA and Vivek S Trivedi, BS
Grant Medical Center, Columbus, OH
47
Dexmedetomidine as adjunctive therapy in alcohol withdrawal syndrome patients in an intensive care unit
Jennifer L. Grelle, Pharm.D., Shawna E. King, Pharm.D., BCPS and Krystal K. Haase, Pharm.D., FCCP, BCPS
Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX
88
Comparison of Polyethylene Glycol – Electrolyte Solution vs. Polyethylene Glycol – 3350 for the Treatment of Fecal Impaction in Pediatric Patients
Erin Boles, Pharm.D.1 and Emma M. Tillman, Pharm.D.2
1Le Bonheur Children's Hospital, Memphis, TN
2University of Tennessee Health Science Center, Memphis, TN
89E
Efficacy, Safety and Tolerability of HZT-501, Including Users of Low-Dose Aspirin (LDA), a Single-Tablet Combination of Ibuprofen-Famotidine: Results of Two Phase 3 Trials
Michael Weinblatt, MD1, Mark C. Genovese, MD2, Alan Kivitz, MD3, Alfonso E. Bello, MD4, Amy Grahn, MS5, Jeffrey W. Sherman, MD, FACP5, Michael H. Schiff, MD6 and Merrell Magelli, PharmD5
1Brigham and Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA
2Stanford University Medical Center, Stanford, CA
3Altoona Center for Clinical Research, Duncansville, PA
4Illinois Bone & Joint Institute, Glenview, IL
5Horizon Pharma, Inc, Northbrook, IL
6Rheumatology Division, University of Colorado, Denver, CO
90
Risk factors associated with hospital-origin vs. community-origin Clostridium difficile-associated diarrhea
Bonnie Dean, PhD1, Rebecca S. Campbell, MD, MPH1, Brian H. Nathanson, PhD2, Tracy Haidar, MS1, Marcie E. Strauss, MPH3 and Sheila Thomas, PharmD3
1Cerner LifeSciences Consulting, Culver City, CA
2OptiStatim, LLC, Longmeadow, MA
3Optimer Pharmaceuticals, Inc., Jersey City, NJ
109
Reducing fluoroquinolone use in the adult emergency department of a community hospital
Yesenia Camero, Pharm.D., Erika Dittmar, Pharm.D., BCPS, Radhan Gopalani, Pharm.D., BCPS and Heidi Clarke, Pharm.D.
Baptist Hospital of Miami, Miami, FL
110E
Evaluating the use of procalcitonin as a biomarker for infection in a medical intensive care unit
Chung-Shien Lee, Pharm.D., Rubiya Azmiree, Pharm.D., BCPS and Rehana Jamali, Pharm.D.
North Shore University Hospital, Manhasset, NY
111
Implementing antimicrobial stewardship in a community hospital
Jordan Walter, PharmD, Radhan Gopalani, PharmD, BCPS and Heidi Clarke, PharmD
Baptist Hospital of Miami, Miami, FL
112
Protease inhibitors: beyond anti-viral property
Talia Mazidi, PharmD, Khandaker Anwar, M.D, Richard M Novak, M.D and Mahmood Ghassemi, Ph.D
University of Illinois at Chicago, Chicago, IL
113
Inhibition of mitochondrial oxidative phosphorylation with anidulafungin
Kayla R. Stover, Pharm.D., BCPS1, Jonathan P. Hosler, Ph.D.2 and John D. Cleary, Pharm.D.2
1School of Pharmacy, The University of Mississippi School of Pharmacy, Jackson, MS
2University of Mississippi Medical Center, Jackson, MS
114
Impact of clinical pharmacist interventions with infectious disease team
Eyad T. Almadhoun, clinical, pharmacist, infectious, disease
Hamad Medical Corporation, Doha, Qatar
115
Retrospective review of antimicrobial selection for treatment of Enterobacter in a teaching hospital
Maria Pompili, PharmD, Aaron Cumpston, PharmD, Michael Sweet, PharmD and Arif Sarwari, MD
West Virginia University Healthcare, Morgantown, WV
116E
Population pharmacokinetic (PPK) analysis of ceftaroline (CPT) in patients with complicated skin and skin structure infection (cSSSI) or community-acquired pneumonia (CAP)
Scott A. Van Wart, MS1, Alan Forrest, PharmD1, Tatiana Khariton, PhD2, Christopher M. Rubino, PharmD, BCPS1, Sujata M. Bhavnani, PharmD, MS1, Todd Riccobene, PhD2 and Paul G. Ambrose, PharmD, FIDSA1
1Institute for Clinical Pharmacodynamics, Latham, NY
2Forest Research Institute, Inc., Jersey City, NJ
117E
A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline fosamil plus avibactam (CXL) administered by intravenous (IV) infusion to healthy subjects
Todd Riccobene, PhD1, Sheng Fang Su, PhD1 and Douglas R. Rank, MD2
1Forest Research Institute, Inc., Jersey City, NJ
2Cerexa, Inc. (a wholly owned subsidiary of Forest Laboratories, Inc., New York, NY), Oakland, CA
118E
Efficacy and safety of tedizolid phosphate for 6 days vs. linezolid for 10 days in a phase 3 study in patients with ABSSSI using the new FDA primary outcome measure
Carisa De Anda, PharmD1, Edward Fang, MD1, Purvi Mehra, MD2, Sinikka Green, MD2 and Philippe Prokocimer, MD1
1Trius Therapeutics, San Diego, CA
2eStudySite, San Diego, CA
119E
Effects of tedizolid phosphate and linezolid on platelet counts in a phase 3 ABSSSI study
Edward Fang, MD1, Carisa De Anda, PharmD1, Anita F. Das, PhD2 and Philippe Prokocimer, MD1
1Trius Therapeutics, San Diego, CA
2AxiStat, Inc., San Francisco, CA
120E
Favorable adverse event profile of tedizolid phosphate compared to linezolid in a phase 3 ABSSSI study
Edward Fang, MD1, Carisa De Anda, PharmD1, Anita F. Das, PhD2 and Philippe Prokocimer, MD1
1Trius Therapeutics, San Diego, CA
2AxiStat, Inc., San Francisco, CA
121
Appropriate use of in vitro susceptibility testing in the selection of antifungal therapy
Shaily Arora, Pharm.D., Rebecca Gayle, PharmD and B. Joseph Guglielmo, PharmD
University of California San Francisco, San Francisco, CA
122E
Comparative potency of oxazolidinones tedizolid (TR-700) and linezolid against target gram-positive pathogens in the US from 2009-2010
Chris Pillar, PhD1, Daniel Sahm, PhD1 and Ken Bartizal, PhD2
1Eurofins Medinet, Chantilly, VA
2Trius Therapeutics, San Diego, CA
123
Therapeutic Drug Monitoring of Posaconazole in Adults: a Retrospective Analysis
Timothy J. Jancel, Pharm.D.1, Scott R. Penzak, Pharm.D.1, Pamela A. Shaw, Ph.D.2, Claire W. Hallahan, M.S.2, Harry L. Malech, M.D.3, Alexandra F. Freeman, M.D.4, Kenneth N. Olivier, M.D.4 and Steven M. Holland, M.D.4
1National Institutes of Health, Bethesda, MD
2National Institute of Allergy and Infectious Diseases (BRB), Bethesda, MD
3National Institute of Allergy and Infectious Diseases (LHD), Bethesda, MD
4National Institute of Allergy and Infectious Diseases (LCID), Bethesda, MD
124E
An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects
Howard Dreskin, MS, Teresa Boyea, PharmD, Jeff Barker, BS, Edward Fang, MD, Shawn Flanagan, PhD and Philippe Prokocimer, MD
Trius Therapeutics, San Diego, CA
125E
Improved pharmacokinetics of the novel oxazolidinone antibiotic tedizolid phosphate compared with linezolid in healthy subjects
Shawn Flanagan, PhD1, Kelly A. Munoz, BA, MA1, Sonia Minassian, DrPH1, Claudette Bethune, PhD2, John Bohn, BS2, Robert Wright, BS2, Paul Bien, MS1 and Philippe Prokocimer, MD1
1Trius Therapeutics, San Diego, CA
2Covance, Madison, WI
126
Correlation of cefpodoxime susceptibility with cephalothin, cefuroxime, and ceftriaxone for urinary tract isolates
David A. Bookstaver, Pharm.D., Christopher M Bland, Pharm.D., Mitchell W Woodberry, Ph.D. and Karon B Mansell, M.T.(ASCP)SM
Eisenhower Army Medical Center, Fort Gordon, GA
127
Vancomycin dosing requirements in obese patients
Mitchell S. Buckley, Pharm.D., FCCM, BCPS1, Julie A. McIndoo, Pharm.D.1, Aundrea R. Linn, Pharm.D.1, Marianna Yanashyan, Pharm.D.2 and Douglas N. Fish, PharmD, BCPS3
1Banner Good Samaritan Medical Center, Phoenix, AZ
2University of Colorado School of Pharmacy, Aurora, CO
3University of Colorado Anschutz Medical Campus, Aurora, CO
128
Vancomycin doses of ≥4 grams/day are not associated with nephrotoxicity in obese patients dosed to trough concentrations of 15-20 mg/L
Mitchell S. Buckley, Pharm.D., FCCM, BCPS1, Julie A. McIndoo, Pharm.D.1, Aundrea R. Linn, Pharm.D.1, Marianna Yanashyan, Pharm.D.2 and Douglas N. Fish, PharmD, BCPS3
1Banner Good Samaritan Medical Center, Phoenix, AZ
2University of Colorado School of Pharmacy, Aurora, CO
3University of Colorado Anschutz Medical Campus, Aurora, CO
129E
Evaluation of ATLAS score in predicting clinical cure and recurrence of Clostridium difficile infection (CDI)
Shauna M. Jacobson, PharmD1 and Douglas Slain, Pharm.D., BCPS2
1West Virginia University Healthcare, Morgantown, WV
2West Virginia University School of Pharmacy, Morgantown, WV
130E
Clinically-derived mutations in ERG11 caused decreased fluconazole susceptibility when expressed in a susceptible strain of C. albicans
Stephanie A. Flowers, Pharm., D.1, Katherine S. Barker, Ph.D.2 and P. David Rogers, Pharm.D., Ph.D.2
1University of Tennessee, Memphis, TN
2University of Tennessee College of Pharmacy, Memphis, TN
131
Transcriptional regulation of fluconazole susceptibility in Candida parapsilosis
Eileen Wanamaker, BS1, Minlu Zhang, Ph.D.2, Long J. Lu, Ph.D.2, Phillip J. Dexheimer, MS2 and Kelly E. Caudle, Pharm.D., Ph.D.1
1University of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, OH
2Cincinnati Children's Hospital Medical Center, Cincinnati, OH
132
Doripenem Pharmacokinetics and Pharmacodynamics in Obese Patients Hospitalized in an Intensive Care Unit
Michael B. Kays, Pharm.D.1, Megan R. Fleming, Pharm.D.2, S. Christian Cheatham, Pharm.D.3, Christina E.K. Chung, Pharm.D.1 and JoEtta Juenke, BS, C(ASCP)4
1Purdue University College of Pharmacy, Indianapolis, IN
2Methodist Dallas Medical Center, Dallas, TX
3Franciscan St. Francis Health — Indianapolis, Indianapolis, IN
4ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT
133
Comparative Pharmacokinetics and Pharmacodynamics of Doripenem and Meropenem in Obese Patients
Michael B. Kays, Pharm.D.1, Megan R. Fleming, Pharm.D.2, S. Christian Cheatham, Pharm.D.3, Christina E. K. Chung, Pharm.D.1 and JoEtta Juenke, BS, C(ASCP)4
1Purdue University College of Pharmacy, Indianapolis, IN
2Methodist Dallas Medical Center, Dallas, TX
3Franciscan St. Francis Health — Indianapolis, Indianapolis, IN
4ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT
134
Population Pharmacokinetics and Pharmacodynamics of Piperacillin, Administered with Tazobactam by Prolonged Infusion, in Morbidly Obese and Non-Obese Patients
Christina E. K. Chung, Pharm.D.1, S. Christian Cheatham, Pharm.D.2, Megan R. Fleming, Pharm.D.3 and Michael B. Kays, Pharm.D.1
1Purdue University College of Pharmacy, Indianapolis, IN
2Franciscan St. Francis Health — Indianapolis, Indianapolis, IN
3Methodist Dallas Medical Center, Dallas, TX
135
Evaluation of compatibility and stability of daptomycin in an antibiotic-anticoagulant lock solution
P. Brandon Bookstaver, PharmD, BCPS, (AQ-ID), AAHIVE, Padmavathy N. Premnath, MPharm, PhD-Candidate and Julie M. Edwards, PharmD-Candidate
South Carolina College of Pharmacy-USC Campus, Columbia, SC
136
Recurrent Clostridium difficile infection (rCDI) is a risk factor for rehospitalization
Marya D. Zilberberg, MD, MPH1, Kimberly Reske, MPH2, Kerry Bommarito, MPH2, Margaret Olsen, PhD, MPH2, Yan Yan, MD, PhD1, Marcie E. Strauss, MPH3 and Erik Dubberke, MD, MSPH1
1EviMed Research Group, LLC, Goshen, MA
2Washington University School of Medicine, St. Louis, MO
3Optimer Pharmaceuticals, Inc., Jersey City, NJ
137E
Comparison of bacterial pneumonia etiology in dialysis versus non-dialysis patients
Nicole C. Farrell, Pharm.D., Jason M. Cota, Pharm.D., M.S., Cheryl K. Horlen, Pharm.D. and Russell T. Attridge, Pharm.D., M.S.
University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX
138
Daptomycin outcomes by duration of methicillin-resistant Staphylococcus aureus bacteremia with vancomycin MIC > 1mg/L
Kenneth C. Lamp, PharmD, Maria I. Amodio-Groton, PharmD and Min J. Yoon, MPH
Cubist Pharmaceuticals, Lexington, MA
139
Assessment and Evaluation efficacy of a clinical pharmacist-led inpatient warfarin knowledge education program and follow up at a Chinese Tertiary referral teaching Hospital
Guy-Armel Bounda, B.Sc(Pharm), M.Sc(Clin, Pharm), PhD.Candidate(Clin, Pharm)1, Cosette Ngarambe, B.Sc(Med)2, Wei Hong GE, B.Sc(Pharm), M.Sc(Clin., Pharm)3 and Feng Yu, B.Sc(Med), M.Sc, PhD1
1China Pharmaceutical University, Nanjing, China
2Southeast University, Nanjing, China
3The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
147
ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical & Health Economics Outcomes Registry in Cervical Dystonia): A Multicenter, Observational Study of Dysport in Cervical Dystonia: Baseline Data and Cycle One Outcomes Data
Jack J. Chen, PharmD1, Richard M. Trosch, MD2, Cynthia L. Comella, MD3, Steven B. Hall, RPh4, Yavuz Silay, MD, MBA4, Chandra M. Coleman, PhD4, Stephen F. Chang, PhD4 and Dominic Marchese, RPh4
1Loma Linda University, Loma Linda, CA
2Oakland University, William Beaumont School of Medicine, Southfield, MI
3Rush University Medical Center, Chicago, IL
4Ipsen Biopharmaceuticals, Basking Ridge, NJ
148
Relationship between the metabolic syndrome and C-reactive protein with stroke prevalence
Stacy A. Voils, Pharm.D.
Virginia Commonwealth University Health System, Richmond, VA
166E
Success of A Methadone Treatment Protocol in Neonatal Drug Withdrawal Following in-Utero Exposure to Substances of Abuse
Varsha Bhatt-Mehta, MS, (CRDSA), Pharm.D., FCCP, Robert E. Schumacher, MD and Chee M. Ng, Pharm.D., Ph.D, FCP
University of Michigan, Ann Arbor, MI
167
Characterization and Evaluation of Clinical Decision Support Dosing Alerts for Medications Prescribed among Pediatric Patients
Jeremy S. Stultz, PharmD1, Karl A. Matuszewski, PharmD, MS2, Gregory H. Dorn, MD, MPH2 and Milap C. Nahata, PharmD, MS1
1Ohio State University College of Pharmacy, Columbus, OH
2First Databank, Inc., South San Francisco, CA
168
Vancomycin Pharmacologic Modeling in Critically-Ill Children Following Modified IDSA Guidelines
Christopher L. Shaffer, PharmD, MS, BCPS
University of Nebraska Medical Center, Omaha, NE
169
Lack of association of late onset sepsis with ranitidine use in neonates
Chasity M. Shelton, Pharm.D., Jasmine K. Sahni, Pharm.D., Ramsubbareddy Dhanireddy, M.D. and Michael L. Christensen, Pharm.D.
The University of Tennessee Health Science Center & Le Bonheur Children's Hospital, Memphis, TN
170E
Don't Leave Without Them: Dispensing asthma medications to pediatric patients upon discharge is associated with decreased hospital readmissions
Kelly J. Hiteshew, PharmD1, Thaddeus Franz, PharmD1, Kristen Lamberjack, PharmD2 and Aleda M. H. Chen, PharmD, PhD1
1Cedarville University School of Pharmacy, Cedarville, OH
2Nationwide Children's Hospital, Columbus, OH
171
Effectiveness of alprostadil dose titration in neonates with congenital heart disease
Marcia L. Buck, Pharm.D., D. Scott Lim, MD and Joshua Attridge, MD
University of Virginia Children's Hospital, Charlottesville, VA
172
The impact of a training program on pharmacists' comfort with pediatric pharmacy concepts and basic pediatric knowledge
Elizabeth A. Riney, PharmD1, Andrew J. Crannage, PharmD, BCPS2, Nausheen Hasan, PharmD3, Rachel M. Tanner, PharmD, BCPS3 and Julie A. Murphy, PharmD, BCPS, FASHP, FCCP1
1St. Louis College of Pharmacy / Mercy Hospital St. Louis, St. Louis, MO
2St. Louis College of Pharmacy, St. Louis, MO
3Mercy Hospital St. Louis, St. Louis, MO
173
Evaluation of a Trace Element Dosing Protocol During Trace Element Product Shortages
Catherine M. Crill, Pharm.D., Rebecca F. Chhim, Pharm.D. and Chasity M. Shelton, Pharm.D.
The University of Tennessee Health Science Center, Memphis, TN
174
Evaluation of Premixed Parenteral Nutrition Solutions in Children
Rebecca F. Chhim, Pharm.D., Ryan O'Neal, B.S. and Catherine M. Crill, Pharm.D.
The University of Tennessee Health Science Center, Memphis, TN
175E
Evaluation of Microbial Contamination Associated with Pharmacy Preparation of Intravenous Fat Emulsion
Kelly Walls, Pharm.D.1, Rebecca F. Chhim, Pharm.D.2 and Catherine M. Crill, Pharm.D.2
1Le Bonheur Children's Hospital, Memphis, TN
2The University of Tennessee Health Science Center, Memphis, TN
176
Using observational data to inform the design of a prospective effectiveness study for a novel insulin delivery device
Yong Chen, Ph.D.1, Matthew Nguyen, PharmD2, Michael Grabner, PhD1 and Ralph Quimbo, MA1
1HealthCore, Inc., Wilmington, DE
2Valeritas, Inc., Bridgewater, NJ
177
Risk of Venous Thromboembolism Complications Associated with Recurrent Venous Thromboembolism
Patrick Lefebvre, MA1, François Laliberté, MA1, Edith A. Nutescu, PharmD2, Mei Sheng Duh, MPH, ScD3, Joyce C. LaMori, MHS, MBA4, Brahim Bookhart, MBA, MPH4, William H. Olson, PhD4, Katherine Dea, MA1, Yvonnick Hossou, BA1, Jeff Schein, DrPH, MPH4 and Scott Kaatz, DO5
1Groupe d'Analyse, Ltée., Montreal, QC, Canada
2University of Illinois at Chicago College of Pharmacy, Chicago, IL
3Analysis Group, Inc., Boston, MA
4Janssen Scientific Affairs, LLC, Raritan, NJ
5Henry Ford Hospital, Detroit, MI
178E
Incremental economic burden of Clostridium-difficile associated diarrhea among hospitalized patients at high risk of recurrent infection
Swetha Rao Palli, MS1, Ralph A. Quimbo, MA1, Joseph R. Singer, MD1, Marcie E. Strauss, MPH2 and Sheila Thomas, PharmD2
1HealthCore Inc., Wilmington, DE
2Optimer Pharmaceuticals, Inc., Jersey City, NJ
179E
Post-hospitalization discharge economic burden of Clostridium-difficile associated diarrhea among high-risk patient sub-groups in a managed care setting
Swetha Rao Palli, MS1, Sheila Thomas, PharmD2, Ralph A. Quimbo, MA1 and Marcie E. Strauss, MPH2
1HealthCore Inc., Wilmington, DE
2Optimer Pharmaceuticals, Inc., Jersey City, NJ
180
Use of a Medication Access and Adherence Tool (MAAT) to identify patients at high risk for medication-related problems
Kim C. Coley, Pharm.D.1, Amy C. Donihi, PharmD1, Rima A. Mohammad, PharmD, BCPS1, Jenny Kim, Pharm.D.2 and Patricia D. Kroboth, PhD1
1University of Pittsburgh School of Pharmacy, Pittsburgh, PA
2Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA
181
Evaluation of medication adherence in a medically underserved population
Bradley M. Wright, PharmD, BCPS1, Karen Marlowe, Pharm, D, BCPS1 and Errol Crook, MD2
1Auburn University, Harrison School of Pharmacy, Mobile, AL
2University of South Alabama - Department of Internal Medicine, Mobile, AL
182
Economic evaluations of clinical pharmacy services: 2006-2010
Daniel R. Touchette, PharmD, MA, FCCP1, Fred Doloresco, MS, PharmD2, Katie J. Suda, PharmD, MS3, Alexandra Perez, PharmD4, Stuart Turner, BPharm, MPH5, Yash J. Jalundhwala, BPharm, MS1, Maria C. Tangonan, BS, PharmD candidate1 and James M. Hoffman, Pharm.D., M.S., BCPS6
1University of Illinois at Chicago, Chicago, IL
2SUNY: University at Buffalo, Buffalo, NY
3University of Tennessee Health Science Center, College of Pharmacy, Memphis, TN
4Nova Southeastern University, Ft. Lauderdale, FL
5University at Buffalo, Buffalo, NY
6St. Jude Children's Research Hospital, Memphis, TN
189
Community pharmacists' attitudes towards pharmacogenetic testing
Sony Tuteja, Pharm.D., BCPS1, Kevin Haynes, PharmD1, Cara Zayac, MPH1, Jon E. Sprague, PhD2, Barbara Bernhardt, MS1 and Reed Pyeritz, MD, PhD1
1University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
2Ohio Northern University Raabe College of Pharmacy, Ada, OH
191
Drug-drug interaction between pramipexole and cimetidine, an OCT2 inhibitor
Byung-Sung Kang, Ph.D., Candidate, Hye-In Lee, M.S. and Chang-Ik Choi, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
192
Effects of CYP2C9 genetic polymorphism on the pharmacokinetics of zafirlukast
Mi-Jung Kim, Ph.D., Candidate, Choon-Gon Jang, Ph.D. and Seok-Yong Lee, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
193
Effects of CYP2C19 genetic polymorphism on the disposition of atomoxetine and its major metabolites
Mi-Jung Kim, Ph.D., Candidate, Choon-Gon Jang, Ph.D. and Seok-Yong Lee, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
194
Pharmacokinetics and pharmacodynamics of meloxicam in relation to CYP2C9 genotype
Mi-Jung Kim, Ph.D., Candidate, Choon-Gon Jang, Ph.D. and Seok-Yong Lee, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
195
CYP2C9 genetic polymorphism significantly affected the pharmacokinetics of candesartan and its metabolite
Ji-Yeong Byeon, B.S., Jung-In Park, B.S., Choon-Gon Jang, Ph.D. and Seok-Yong Lee, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
196
Effects of ABCC2 C-24T genetic variant on the pharmacokinetics of valsartan in healthy Koreans
Ji-Yeong Byeon, B.S., Jung-In Park, B.S., Choon-Gon Jang, Ph.D. and Seok-Yong Lee, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
197
Effects of CYP2C9*3 and CYP2C9*13 alleles on the pharmacokinetics of celecoxib and its carboxylic metabolite
So-Young Park, B.S., Hye-In Lee, Ph.D. Candidate and Chang-Ik Choi, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
198
Dose adjustment of celecoxib based on CYP2C9 genotype in healthy Koreans
So-Young Park, B.S., Hye-In Lee, Ph.D. Candidate and Chang-Ik Choi, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
199
CYP2C9 genotype dependent inhibition of gastric acid secretion by omeprazole
So-Young Park, B.S.1, Chang-Ik Choi, Ph.D.1 and Jung-Woo Bae, Ph.D.2
1School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2College of Pharmacy, Keimyung University, Daegu, South Korea
200
Dose optimization of omeprazole according to the CYP2C19 genotype
So-Young Park, B.S.1, Jung-Woo Bae, Ph.D.2 and Chang-Ik Choi, Ph.D.1
1School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2College of Pharmacy, Keimyung University, Daegu, South Korea
201
CYP2C19 genotype: a moving target?
Tracy N. Zembles, Pharm.D., Charles J. Marcuccilli, PhD, MD, Tara L. Sander, PhD and Pippa Simpson, PhD
Childen's Hospital of Wisconsin, Milwaukee, WI
202
Effects of CYP3A5 genetic polymorphism on the pharmacokinetics of tamsulosin in subjects with with CYP2D6*10/*10
Ji-Yeong Byeon, B.S., Choon-Gon Jang, Ph.D. and Seok-Yong Lee, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
203
NOTCH3: A Potential Predictive Biomarker in Malignant Glioma
Mohammad A. Y. Alqudah, PharmD1, Supreet Agarwal, B.Sc1, Maha S. Al-Keilani, PharmD1, Zita Sibenaller, PhD2, Timothy C. Ryken, MD2 and Mahfoud Assem, PhD1
1University of Iowa, Pharmaceutics and Translational Therapeutics, Iowa, IA
2University of Iowa, Neurosurgery Department, Iowa, IA
204
Improvement of vancomycin utilization in a community teaching hospital
Brenda Gitman, PharmD., Rani Patel, PharmD. and Joseph Gugliotta, MD
Hunterdon Medical Center, Flemington, NJ
205
Evaluation of digoxin pharmacokinetics in a patient undergoing continuous venovenous hemofiltration
Scott T. Benken, PharmD and Bryan D. Lizza, PharmD
Northwestern Memorial Hospital, Chicago, IL
206
Is a standard vancomycin dosing protocol appropriate to achieve therapeutic trough levels in adult neutropenic patients?
Kellye A. Donovan, Pharm.D. and Julie Sklenicka, Pharm.D.
Naval Medical Center San Diego, San Diego, CA
207
Pharmacokinetics of vancomycin in patients with continuous flow left-ventricular assist devices
Charles T. Makowski, PharmD1, Rachel M. Chambers, PharmD, BCPS, (AQ-ID)2 and Douglas L. Jennings, PharmD, BCPS, (AQ-CV)2
1Wayne State University Eugene Applebaum College of Pharmacy, Detroit, MI
2Henry Ford Hospital, Detroit, MI
208
Linagliptin fixed-dose combination with metformin is bioequivalent to free-pill combination therapy
Susanne Buschke, Ph.D., Arne Ring, M.D., Christian Friedrich, M.D., Katrin Metzmann, M.D. and Thomas Meinicke, M.D.
Boehringer Ingelheim, Biberach, Germany
209
Drug-drug interaction between tamsulosin and diltiazem, a moderate CYP3A4 inhibitor
Ji-Yeong Byeon, B.S., Jung-In Park, B.S., Choon-Gon Jang, Ph.D. and Seok-Yong Lee, Ph.D.
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
210
Food and tablet dissolution characteristics do not affect the bioavailability of linagliptin fixed-dose combination with metformin
Katrin Metzmann, M.D.1, David Schnell, Ph.D.2, Arvid Jungnik, M.D.1, Arne Ring, M.D.1, Rudolf Theodor, M.D.3, Kathrin Hohl, Ph.D1, Thomas Meinicke, M.D.1 and Christian Friedrich, M.D.1
1Boehringer Ingelheim, Biberach, Germany
2SocraMetrics GmbH, Erfurt, Germany
3ClinPharm Reform GmbH, Ulm, Germany
211
Impact of Hispanic ethnicity on tacrolimus dosing in liver transplant patients
Annelise M. Nelson, PharmD, BCPS, Christina T. Doligalski, PharmD, BCPS, Angela T. Logan, PharmD, Andrew Silverman, PharmD and Angel Alsina, MD
Tampa General Hospital, Tampa, FL
212
Modeling of aceclofenac metabolism to major metabolites in healthy volunteers
Eunyoung Kim, PharmD, Ph.D1 and Wonku Kang, PhD2
1Chungnam National University, Daejeon, South Korea
2Yeungnam University, Kyoungsan, South Korea
213
Cytochrome P450 3A4 drug interaction profile of tofacitinib
Sriram Krishnaswami, PhD1, Manisha Lamba, PhD, MPharm1, Pankaj Gupta, PhD1, Liza Takiya, PharmD, BCPS2, Ronnie Wang, MPH1, Irina Kaplan, PhD1, Joanne Salageanu, PhD1, Sanela Tarabar, MD1, Christine Alvey, BS1 and Marie-Noella Ndongo, MD3
1Pfizer, Groton, CT
2Pfizer, Collegeville, PA
3Pfizer, Brussels, Belgium
214
Ethanol inhibits the metabolism of oseltamivir to its active metabolite
Robert B. Parker, Pharm.D.1, Bernd Meibohm, Ph.D.2, Zheyi Hu, Ph.D.1 and S. Casey Laizure, Pharm.D.1
1University of Tennessee Department of Clinical Pharmacy, Memphis, TN
2University of Tennessee Department of Pharmaceutical Sciences, Memphis, TN
215
Three cases of iatrogenic adrenal insufficiency due to concomitant administration of posaconazole and budesonide
Timothy J. Jancel, Pharm.D.1, Scott R. Penzak, Pharm.D.1, Kenneth N. Olivier, M.D.2, Gulbu Uzel, M.D.2 and Steven M. Holland, M.D.2
1National Institutes of Health, Bethesda, MD
2National Institute of Allergy and Infectious Diseases (LCID), Bethesda, MD
216
The vasculo-protective effect of candesartan after ischemic stroke: an Antioxidant
Ahmed Alhusban, Pharm.D1, Anna Kozak, M.S.2, Tauheed Isharat, Ph.D.3, Bindu Pillai, MS3 and Susan C. Fagan, PharmD3
1University of Georgia, Augusta, GA
2University of Georgia College of Pharmacy and Veteran's Affairs Medical Center, Augusta, GA
3Program in Clinical and Experimental Therapeutics University of Georgia College of Pharmacy Charlie Norwood VA Medical Center Au, Augusta, GA
217E
In Vitro Activity of Colistin Alone and in Combination with Doripenem against KPC-producing K. pneumoniae Isolates
Grace C. Lee, Pharm.D, BCPS and David S. Burgess, Pharm.D., FCCP
University of Texas at Austin College of Pharmacy and University of Texas Health Science Center School of Medicine, San Antonio, TX
218
Evaluation of the maternal-fetal transfer of granisetron in an ex vivo placenta perfusion model
Judith A. Smith, Pharm.D., BCOP, FCCP, FISOPP1, Justin Julius, Pharm.D.2, Andrew Tindall, B.S.3, Jerrie Refuerzo, M.D.4, Pamela D. Berens, M.D.4 and Kenneth Moise, M.D.4
1UT M. D. Anderson Cancer Center, Houston, TX
2The UT MD Anderson Cancer Center, Houston, TX
3UT MD Anderson Cancer Center, Houston, TX
4University of Texas Health Sciences Center at Houston Medical School, Houston, TX
221E
Indacaterol 75 mcg Once Daily Improves Health Status in Patients with Moderate-to-severe COPD: Responder Analysis
Donald A. Mahler, MD1, Leonard J. Dunn, MD2, Mark H. Gotfried, MD3, James Williams, MD4, David Lawrence, PhD5 and Danny McBryan, MD6
1Dartmouth-Hitchcock Medical Center, Lebanon, NH
2Clinical Research of West Florida, Clearwater, FL
3Pulmonary Associates, Phoenix, AZ
4Novartis Pharmaceuticals Corporation, East Hanover, NJ
5Novartis Pharmaceuticals UK Limited, Horsham,, West Sussex RH12 5AB, United Kingdom
6Novartis Pharma AG, CH-4002 Basel, Switzerland
222E
Efficacy and Safety of Indacaterol 75 mcg Once Daily in Patients with Moderate-to-Severe COPD: Pooled Analysis of Two Phase III trials
James F. Donohue, MD1, Thomas Siler, MD2, Edward M. Kerwin, MD3, James Williams, MD4, Farid Kianifard, PhD4 and Danny McBryan, MD5
1University of North Carolina, School of Medicine, Chapel Hill, NC
2Midwest Chest Consultants, PC, Saint Charles, MO
3Allergy & Asthma Center of Southern Oregon, Medford, OR
4Novartis Pharmaceuticals Corporation, East Hanover, NJ
5Novartis Pharma AG, CH-4002 Basel, Switzerland
223E
Chronic obstructive pulmonary disease outcomes based on level of short-acting B2-agonist use
Amir Sharafkhaneh, MD, PhD1, Nicola A. Hanania, MD, MS, FCCP, FRCP(C), FACP2, Gene L. Colice, MD3, James D. Donahue, MD4, Aylin Riedel, PhD5, Jonathan Kurlander, MS5, Pablo R. Altman, MD, MBA6, John Howard, PharmD6 and Joe Harper, PharmD6
1Michael E. Debakey VA Medical Center, Houston, TX
2Baylor College of Medicine, Houston, TX
3Washington Hospital Center, Washington, DC
4University of North Carolina School of Medicine, Chapel Hill, NC
5OptumInsight, Eden Prairie, MN
6Mylan Specialty L.P., Basking Ridge, NJ
See more of: Original Research
<< Previous Session | Next Session >>